Intrathecal administration of AAV/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant

Globoid cell leukodystrophy (GLD), or Krabbe disease, is an autosomal recessive neurodegenerative disease caused by the deficiency of the lysosomal enzyme galactocerebrosidase (GALC). Hematopoietic stem cell transplantation (HSCT) provides modest benefit in presymptomatic patients but is well short...

Full description

Saved in:
Bibliographic Details
Published inJournal of neuroscience research Vol. 94; no. 11; pp. 1138 - 1151
Main Authors Karumuthil-Melethil, Subha, Marshall, Michael S., Heindel, Clifford, Jakubauskas, Benas, Bongarzone, Ernesto R., Gray, Steven J.
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.11.2016
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Globoid cell leukodystrophy (GLD), or Krabbe disease, is an autosomal recessive neurodegenerative disease caused by the deficiency of the lysosomal enzyme galactocerebrosidase (GALC). Hematopoietic stem cell transplantation (HSCT) provides modest benefit in presymptomatic patients but is well short of a cure. Gene transfer experiments using viral vectors have shown some success in extending the survival in the mouse model of GLD, twitcher mice. The present study compares three single‐stranded (ss) AAV serotypes, two natural and one engineered (with oligodendrocyte tropism), and a self‐complementary (sc) AAV vector, all packaged with a codon‐optimized murine GALC gene. The vectors were delivered via a lumbar intrathecal route for global CNS distribution on PND10–11 at a dose of 2 × 1011 vector genomes (vg) per mouse. The results showed a similar significant extension of life span of the twitcher mice for all three serotypes (AAV9, AAVrh10, and AAV‐Olig001) as well as the scAAV9 vector, compared to control cohorts. The rAAV gene transfer facilitated GALC biodistribution and detectable enzymatic activity throughout the CNS as well as in sciatic nerve and liver. When combined with BMT from syngeneic wild‐type mice, there was significant improvement in survival for ssAAV9. Histopathological analysis of brain, spinal cord, and sciatic nerve showed significant improvement in preservation of myelin, with ssAAV9 providing the greatest benefit. In summary, we demonstrate that lumbar intrathecal delivery of rAAV/mGALCopt can significantly enhance the life span of twitcher mice treated at PND10–11 and that BMT synergizes with this treatment to improve the survival further. © 2016 Wiley Periodicals, Inc. Intrathecal AAV‐mediated gene therapy synergized with bone marrow transplant (BMT) in the 10–11‐day‐old twitcher mouse model of Krabbe disease to extend the survival as well as to improve the pathology in the CNS and sciatic nerve.
Bibliography:ArticleID:JNR23882
Legacy of Angels Foundation
Hunter's Hope Foundation
istex:70193791CE1B8AA938B6EB444C6E0774BBA02D3E
National Institutes of Health - No. F30NS090684; No. R01NS065808; No. R21NS087474
ark:/67375/WNG-8CVXFC5N-8
SIGNIFICANCE Krabbe disease is a devastating neurodegenerative disease. Hematopoietic stem cell transfer with cord blood or donor bone marrow is the current standard of care, which provides some limited efficacy in nonsymptomatic infants and twitcher mice. We report that intrathecal AAV‐mediated gene therapy in 10–11‐day‐old twitcher mice can extend survival and improve pathology. Furthermore, we show that bone marrow transplant synergizes with this approach. We propose that this study models the application of a combined therapy in human infants with Krabbe disease and that the results are an important preclinical step toward the eventual application of gene therapy for Krabbe disease patients.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0360-4012
1097-4547
DOI:10.1002/jnr.23882